

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD  
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

October 19, 2011

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

**AGENDA**

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for the June 29, 2011 meeting (pages 3-6; Tab1)
- IV. Secretary's report (pages 7-8; Tab 2)
- V. New Business
  - A. Proposed protocol for the efficient and safe use of telaprevir (Incivek®) (pages 9-10; Tab 3)
  - B. Proposed protocol for the efficient use of fluticasone/salmeterol (Advair®) (pages 11-14; Tab 4)
  - C. Review of NJ Mandatory Generic Substitution Drug Program (pages 15-18; Tab 5)
- VI. Informational Highlights/Reports
  1. Molina Prior Authorization Report (pages 19-20; Tab 6)
  2. NJ HMO Reports 2<sup>nd</sup> Quarter 2011 (pages 21-24; Tab 7)
  3. DHS and DHSS Programs Top Drugs Report (pages 25 – 38; Tab 8)
  4. FDA Alerts: (pages 39-41; Tab 9)
    - a. High dose simvastatin
    - b. New maximum dosing for acetaminophen
    - c. Varenicline (Chantix®) label change – risk of cardiovascular adverse events